About this episode
Welcome to the Planet MicroCap Podcast’s Due Diligence series. I’m your host, Robert Kraft. My guest today is Dan Goldberger, CEO of electroCore (NASDAQ: ECOR). electroCore is a commercial-stage neuromodulation company developing a suite of non-invasive vagus nerve stimulation devices—delivering a two-minute therapy session designed to rebalance the autonomic nervous system. Built around its nVNS platform, the company operates across three channels: prescription medical devices for headache and migraine, the fast-growing Truvaga direct-to-consumer wellness brand, and a specialized military and government division built around its ruggedized tac-stim product.
Founded in 2006 as a non-invasive alternative to implanted vagus nerve stimulators, electroCore has evolved into a multi-indication business with seven FDA authorizations for headache, serving major customers like the U.S. Department of Veterans Affairs and the UK’s National Health Service. I invited Dan to the show to discuss all of this, as well as:
How nVNS platform works and the science behind vagus nerve modulation
electroCore’s evolution from implanted alternatives to multi-channel neuromodulation
The prescription business model across the VA, NHS, and managed care
Truvaga’s growth in the wellness market and why awareness is the primary competitor
The tac-stim military program and its role as a meaningful revenue stream
Strategic priorities heading into 2026—profitability, capital allocation, and commercial execution
Challenges around insurance coverage and overcoming the “chicken and egg” problem
The path toward becoming a $150–200 million business and the long-term vision for the platform
For more information about electroCore, please visit: https://www.electrocore.com/
This podcast was recorded and is being made available by SNN, Inc. (together with its affiliates and its and their employees, “SNN”) solely for informational purposes. SNN is not providing or undertaking to provide any financial, economic, legal, accounting, tax, or other advice in or by virtue of this podcast. The information, statements, comments, views, and opinions provided in this podcast are general in nature, and such information, statements, comments, views, and opinions, and the viewing of/listening to this podcast are not intended to be and should not be construed as the provision of investment advice by SNN. The information, statements, comments, views, and opinions expressed in this podcast do not constitute and should not be construed as an offer to buy or sell any securities or to make or consider any investment or other course of action.
The information, statements, comments, views, and opinions expressed in this podcast (including by guest speakers who are not officers, employees, or agents of SNN) are not necessarily those of SNN and may not be current. Refere
